申请人:ICHIMARU PHARCOS CO., LTD.
公开号:US20220227813A1
公开(公告)日:2022-07-21
A cyclic peptide or a pharmaceutically acceptable salt of the cyclic peptide includes an amino acid sequence represented by a Formula: c[X
1
-Pro-X
3
-c(Cys-X
5
-Ser-4fF-Asp-Pro-X
10
-X
11
)]. X
1
denotes a residue of β-alanine or γ-aminobutyric acid, X
3
denotes a residue of leucine, norleucine, cyclohexylglycine, phenylglycine, 2-aminoheptanoic acid, 2-aminooctanoic acid, 2-aminononanonic acid, or 2-aminodecanoic acid, X
5
denotes a residue of isoleucine, norleucine, cyclohexylglycine, phenylglycine, 2-aminoheptanoic acid, 2-aminooctanoic acid, 2-aminononanonic acid, or 2-aminodecanoic acid, and X
10
denotes a residue of valine, phenylalanine, tryptophane or an N-methyl derivative thereof, X
11
denotes a residue of D-cysteine or L-cysteine. X
1
and X
11
form an amide bond between an amino group and a carboxy group in their main chains, and Cys and X
11
form a covalent bond between their side chain sulfhydryl groups via a linker of a methylene group, an ethylene group, a propylene group or a butylene group. Therefore, two cyclic structures are present in the amino acid sequence.